title: Eicosopentaneoic Acid and Other Free Fatty Acid Receptor Agonists Inhibit Lysophosphatidic Acid- and Epidermal Growth Factor-Induced Proliferation of Human Breast Cancer Cells.
abstract: Many key actions of ω-3 (n-3) fatty acids have recently been shown to be mediated by two G protein-coupled receptors (GPCRs) in the free fatty acid receptor (FFAR) family, FFA1 (GPR40) and FFA4 (GPR120). n-3 Fatty acids inhibit proliferation of human breast cancer cells in culture and in animals. In the current study, the roles of FFA1 and FFA4 were investigated. In addition, the role of cross-talk between GPCRs activated by lysophosphatidic acid (LPA), and the tyrosine kinase receptor activated by epidermal growth factor (EGF), was examined. In MCF-7 and MDA-MB-231 human breast cancer cell lines, both LPA and EGF stimulated proliferation, Erk activation, Akt activation, and CCN1 induction. LPA antagonists blocked effects of LPA and EGF on proliferation in MCF-7 and MDA-MB-231, and on cell migration in MCF-7. The n-3 fatty acid eicosopentaneoic acid inhibited LPA- and EGF-induced proliferation in both cell lines. Two synthetic FFAR agonists, GW9508 and TUG-891, likewise inhibited LPA- and EGF-induced proliferation. The data suggest a major role for FFA1, which was expressed by both cell lines. The results indicate that n-3 fatty acids inhibit breast cancer cell proliferation via FFARs, and suggest a mechanism involving negative cross-talk between FFARS, LPA receptors, and EGF receptor.
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA 99163, USA. mandi.hopkins@wsu.edu.
authors.forename: Mandi M
authors.initials: MM
authors.lastname: Hopkins
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA 99163, USA. juliazhang2013@gmail.com.
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA 99163, USA. zeliu1010@gmail.com.
authors.forename: Ze
authors.initials: Z
authors.lastname: Liu
authors.affiliation: Department of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA 99163, USA. kmeier@wsu.edu.
authors.forename: Kathryn E
authors.initials: KE
authors.lastname: Meier
keywords: G protein-coupled receptors; breast cancer; epidermal growth factor; free fatty acid receptors; lysophosphatidic acid; ω-3 fatty acids
references.citation: Br J Nutr. 2002 Apr;87(4):281-9
references.pmid: 12064337
references.citation: Biochim Biophys Acta. 2002 May 23;1582(1-3):265-9
references.pmid: 12069837
references.citation: J Nutr. 2002 Nov;132(11 Suppl):3508S-3512S
references.pmid: 12421878
references.citation: Int J Cancer. 2002 Dec 20;102(6):572-9
references.pmid: 12447997
references.citation: Mol Pharmacol. 2003 Oct;64(4):994-1005
references.pmid: 14500756
references.citation: Biochem Biophys Res Commun. 2004 Feb 13;314(3):805-9
references.pmid: 14741707
references.citation: J Clin Invest. 2004 Dec;114(12):1714-25
references.pmid: 15599396
references.citation: Int J Cancer. 2005 Nov 10;117(3):340-8
references.pmid: 15900589
references.citation: J Cell Biol. 2005 Jun 6;169(5):801-11
references.pmid: 15939762
references.citation: Breast Cancer Res Treat. 2005 Jul;92(2):187-95
references.pmid: 15986129
references.citation: J Nutr. 2005 Sep;135(9):2124-9
references.pmid: 16140887
references.citation: Am J Physiol Cell Physiol. 2007 May;292(5):C1927-33
references.pmid: 17496233
references.citation: Int J Oncol. 2008 Jul;33(1):59-67
references.pmid: 18575751
references.citation: Mol Cell Endocrinol. 2008 Nov 6;294(1-2):81-91
references.pmid: 18775472
references.citation: Exp Cell Res. 2008 Nov 1;314(18):3340-55
references.pmid: 18804105
references.citation: Breast Cancer Res Treat. 2009 Nov;118(1):213-28
references.pmid: 18953692
references.citation: Cancer Cell. 2009 Jun 2;15(6):539-50
references.pmid: 19477432
references.citation: Cancer Res. 2009 Jul 1;69(13):5441-9
references.pmid: 19509223
references.citation: Mol Cancer Res. 2009 Jul;7(7):1064-77
references.pmid: 19609003
references.citation: Am J Physiol Cell Physiol. 2010 Jan;298(1):C163-70
references.pmid: 19864325
references.citation: Oncol Res. 2009;18(4):173-84
references.pmid: 20112503
references.citation: Br J Cancer. 2010 Mar 16;102(6):941-6
references.pmid: 20234370
references.citation: Mol Cell Proteomics. 2010 Nov;9(11):2337-53
references.pmid: 20639409
references.citation: Br J Pharmacol. 2010 Aug;160(7):1699-713
references.pmid: 20649573
references.citation: Cell. 2010 Sep 3;142(5):687-98
references.pmid: 20813258
references.citation: PLoS One. 2010 Dec 30;5(12):e15940
references.pmid: 21209852
references.citation: Clin Exp Metastasis. 2011 Aug;28(6):551-65
references.pmid: 21533871
references.citation: J Pharm Sci. 2011 Sep;100(9):3594-601
references.pmid: 21618241
references.citation: Biochim Biophys Acta. 2011 Dec;1810(12):1170-7
references.pmid: 21914461
references.citation: Cancer Metastasis Rev. 2011 Dec;30(3-4):507-23
references.pmid: 22015691
references.citation: Nat Rev Drug Discov. 2011 Dec 01;10(12):945-63
references.pmid: 22129992
references.citation: Cell Commun Adhes. 2011 Dec;18(6):119-30
references.pmid: 22176685
references.citation: Annu Rev Nutr. 2012 Aug 21;32:203-27
references.pmid: 22404117
references.citation: Front Endocrinol (Lausanne). 2012 Jan 03;2:112
references.pmid: 22649399
references.citation: Cancer Res. 2012 Aug 1;72(15):3795-806
references.pmid: 22651929
references.citation: J Natl Cancer Inst. 2012 Sep 5;104(17):1306-19
references.pmid: 22911670
references.citation: Breast Cancer Res Treat. 2012 Nov;136(2):331-45
references.pmid: 23073759
references.citation: PLoS One. 2013;8(2):e56174
references.pmid: 23405264
references.citation: BMJ. 2013 Jun 27;346:f3706
references.pmid: 23814120
references.citation: Br J Pharmacol. 2013 Oct;170(4):696-711
references.pmid: 23937426
references.citation: Mol Pharmacol. 2013 Nov;84(5):710-25
references.pmid: 23979972
references.citation: J Pharmacol Exp Ther. 2014 Oct;351(1):172-80
references.pmid: 25077525
references.citation: Clin Exp Med. 2015 Aug;15(3):371-80
references.pmid: 25209561
references.citation: Oncogene. 2015 Jul;34(27):3504-13
references.pmid: 25220417
references.citation: Nutrients. 2014 Oct 30;6(11):4760-93
references.pmid: 25360510
references.citation: In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):121-7
references.pmid: 25413005
references.citation: J Pharmacol Exp Ther. 2015 Feb;352(2):380-94
references.pmid: 25491146
references.citation: Clin Exp Med. 2016 Feb;16(1):37-47
references.pmid: 25596714
references.citation: J Pharmacol Exp Ther. 2016 Oct;359(1):124-33
references.pmid: 27474750
references.citation: J Natl Cancer Inst. 1984 Aug;73(2):457-61
references.pmid: 6087007
references.citation: J Natl Cancer Inst. 1993 Nov 3;85(21):1743-7
references.pmid: 8411258